17 October 2023
Sidley Represents Novo Nordisk in Collaboration With Evotec SE to Launch Translational Drug Discovery Accelerator, LAB eN²
Advising firms
Deal team
6 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Asher Rubin Lead | Sidley | Partner | Technology and Life Sciences Transactions | Not stated |
| Alison Lehner Lead | Sidley | Partner | Emerging Companies and Venture Capital | Not stated |
| BinQuan Zhuang, Ph.D. Lead | Sidley | Partner | M&A | Not stated |
| Catherine Starks | Sidley | Not stated | Healthcare | Not stated |
| Paul A. Svoboda | Sidley | Not stated | Tax | Not stated |
| John Miscevich | Sidley | Not stated | IP Litigation | Not stated |
3 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- Not stated
- What the figure measures
- Not stated
- Client
- Novo Nordisk Inc.Joint venture party
- Counterparties
- Evotec SE (Joint venture party)